Navigation Links
KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Date:2/27/2008

Third Quarter Revenues Up 38.8%, Nine-Month Revenues Up 40.6% ETHEX Revenue Up 57.8% for Third Quarter, Up 65.2% for Nine Months Ther-Rx

Revenue Up 16.6% for Third Quarter, Up 15.2% for Nine Months

ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) today reported preliminary financial results for the third quarter and first nine months of fiscal 2008 ended December 31, 2007. The results reflected continued acceleration of revenue and profits at both the Company's branded drug subsidiary Ther-Rx Corporation, and generic/non-branded drug subsidiary ETHEX Corporation.

Net revenue, net income and diluted earnings per share amounts for both the third quarter and interim year-to-date periods are preliminary and subject to possible adjustments based upon completion of our financial statements which are being restated to reflect the outcome of a previously disclosed investigation into the Company's stock option grant practices. As previously reported, the New York Stock Exchange has granted an extension for trading of the Company's shares through March 31, 2008 required under the Exchange's rules due to the Company's delayed filing of its fiscal 2007 Annual Report on Form 10-K with the Securities and Exchange Commission. The Company expects by this date to have resolved all outstanding issues needed to make this filing and to complete its fiscal 2007 filings and restatements of previously reported results for the fiscal years 1996-2006.

THIRD QUARTER RESULTS

Net revenues for the third quarter increased 38.8% to $163.7 million, compared to $117.9 million for the third quarter of fiscal 2007. Ther-Rx net revenue grew 16.6% to $56.3 million, while ETHEX net revenues rose 57.8% to $102.2 million. ETHEX net revenue growth was positively affected by important ANDA products including the 100 mg and 200 mg strengths of Metoprolol Succinate Extended Release Tablets (generic alternative to Toprol(R)
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
2. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
3. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
4. Lotus Pharmaceuticals Raises $5 Million in Private Placement
5. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
6. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
7. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
8. RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
9. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
10. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Boulder, Colorado (PRWEB) January 22, 2015 Four years ... is Queen – which coincided with the marriage of Avasa & ... album, THE ROAD, which is scheduled for release through White Swan ... heartfelt message that there is a sacred path available to all ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 As ... of overall health care gains momentum worldwide, Rev. Eric ... HealthCare Chaplaincy Network (HCCN), will be the keynote ... spiritual care in Israel’s public health system. , The conference, ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance of ... the costs of an auto insurance policy . , Clients ... prices for their vehicle insurance policies. The safety a vehicle offers ... Because of this, drivers should always carry a first aid ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... in four men admitted to hospital with acute urinary retention will ... , The risk of death in men after acute urinary retention ... hip. The problem is set to get worse as the population ... sudden inability to pass urine and is often a progression of ...
... Asset Sales and ... Anticipated Pre-Tax Charges ... Va., Nov. 9 Sunrise Senior Living,Inc. (NYSE: SRZ ) today ... 2007. The Company also,provided preliminary information on recapitalizations, asset sales and,anticipated pre- ...
... of chronic hepatitis C and advanced liver disease in ... the disease, a national study in which the Saint ... Patients in the trial who were treated with interferon ... liver inflammation, but the trial unequivocally demonstrated that treatment ...
... benefit from spinal manipulation , , FRIDAY, Nov. 9 ... acute low back pain -- nonsteroidal anti-inflammatory drugs ... patients in a carefully controlled study, Australian researchers ... said, because the evidence for their effectiveness has ...
... Ariz., Nov. 9 Rural/Metro,Corporation (Nasdaq: RURL ) ... quarter ended September 30, 2007 and fiscal 2007 fourth ... opening of markets on November,14, 2007. In conjunction, the ... these results beginning at 9 a.m. (Pacific)/ 11 a.m.,(Eastern). ...
... down due to non-recurring event in 2007, net loss ... in Canadian dollars unless otherwise noted), BELLEVILLE, ON, ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced financial results ... September 30, 2007. "We are also focused on ...
Cached Medicine News:Health News:Study reveals high death toll after severe urinary complications in men over 45 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 3Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 4Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 5Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 6Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 7Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 8Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 9Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 10Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 11Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 12Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 13Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:NSAID Drug Therapy Fails to Ease Back Pain 2Health News:Rural/Metro to Host Conference Call to Discuss Results for First Quarter Fiscal 2008 and Fourth Quarter/Fiscal 2007 Year-End 2Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9Health News:Bioniche Reports Fiscal 2008 First Quarter 10Health News:Bioniche Reports Fiscal 2008 First Quarter 11
(Date:1/23/2015)... , Jan. 23, 2015  HyGreen, Inc., a leader in ... partnership with RCA Medical, a subsidiary of Ascendis Health ... Each year, hundreds of millions of patients ... as organisms are transmitted from patient to patient via ...
(Date:1/23/2015)... 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) ... "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with the ... provides an update for shareholders detailing why a "YES" vote ... Dear Shareholders, As we reflect upon the ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Germany, Jan. 18, 2011 Amgen Inc. (Nasdaq: ... have signed an agreement under which Boehringer Ingelheim will ... Amgen,s Fremont California development and manufacturing facility. ... directors of each company and is expected to close ...
... The Lanier Law Firm and attorneys from around ... status conference involving hip implant cases in In re: DePuy ... 2197 ) . U.S. District Judge David A. ... Ohio is holding the initial coordination hearing in West Palm Beach ...
Cached Medicine Technology:Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 2Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 3Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 4Boehringer Ingelheim to Purchase Amgen's Fremont (California) Facility 5The Lanier Law Firm Readies for First Hearing in Nationwide Hip Implant Litigation 2
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Intended for the quantitative determination of glucose in biological fluids. Reaction: endpoint. Wavelength: 340 nm. Linearity: 800 mg/dL (44.4 mmol/L). Single vial, dry powder reagent....
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dl (27.8 mmol/l). Single vial, dry powder reagent....
Medicine Products: